These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
78 related articles for article (PubMed ID: 25586892)
1. Progestogen safety in multiple gestations: application of the Bradford Hill criteria. O'Brien JM BJOG; 2015 Apr; 122(5):610-4. PubMed ID: 25586892 [No Abstract] [Full Text] [Related]
2. The safety of progesterone and 17-hydroxyprogesterone caproate administration for the prevention of preterm birth: an evidence-based assessment. O'Brien JM Am J Perinatol; 2012 Oct; 29(9):665-72. PubMed ID: 22773279 [TBL] [Abstract][Full Text] [Related]
3. The safety of progestogen in the prevention of preterm birth: meta-analysis of neonatal mortality. Ahn KH; Bae NY; Hong SC; Lee JS; Lee EH; Jee HJ; Cho GJ; Oh MJ; Kim HJ J Perinat Med; 2017 Jan; 45(1):11-20. PubMed ID: 27124668 [TBL] [Abstract][Full Text] [Related]
4. Safety signals of 17-OHP-C use in pregnancy and efficacy in the prevention of preterm birth. Calda P J Matern Fetal Neonatal Med; 2009 Jun; 22(6):540-2. PubMed ID: 19089768 [No Abstract] [Full Text] [Related]
5. Medication safety is still an issue in obstetrics 50 years after the Kefauver-Harris amendments: the case of progestogens. O'Brien JM Ultrasound Obstet Gynecol; 2013 Sep; 42(3):247-53. PubMed ID: 23495199 [No Abstract] [Full Text] [Related]
6. Using 17 α-hydroxyprogesterone caproate to impact rates of recurrent preterm delivery in clinical practice. Rebarber A; Fox NS; Klauser CK; Istwan NB; Rhea DJ; Stanziano GJ; Saltzman DH J Matern Fetal Neonatal Med; 2010 Oct; 23(10):1139-42. PubMed ID: 20170407 [TBL] [Abstract][Full Text] [Related]
7. ACOG Committee Opinion number 419 October 2008 (replaces no. 291, November 2003). Use of progesterone to reduce preterm birth. Society for Maternal Fetal Medicine Publications Committee Obstet Gynecol; 2008 Oct; 112(4):963-5. PubMed ID: 18827143 [No Abstract] [Full Text] [Related]
8. 17α Hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth. Merlob P; Stahl B; Klinger G Reprod Toxicol; 2012 Jan; 33(1):15-9. PubMed ID: 22120850 [TBL] [Abstract][Full Text] [Related]
9. What agent should be used to prevent recurrent preterm birth: 17-P or natural progesterone? Hall NR Obstet Gynecol Clin North Am; 2011 Jun; 38(2):235-46, ix-x. PubMed ID: 21575799 [TBL] [Abstract][Full Text] [Related]
10. Progesterone does not prevent preterm births in women with twins. Briery CM; Veillon EW; Klauser CK; Martin RW; Chauhan SP; Magann EF; Morrison JC South Med J; 2009 Sep; 102(9):900-4. PubMed ID: 19668021 [TBL] [Abstract][Full Text] [Related]
11. 17-hydroxyprogesterone caproate for twin pregnancy: a double-blind, randomized clinical trial. Combs CA; Garite T; Maurel K; Das A; Porto M; Am J Obstet Gynecol; 2011 Mar; 204(3):221.e1-8. PubMed ID: 21376161 [TBL] [Abstract][Full Text] [Related]
18. Reply: To PMID 23295976. Caritis SN Am J Obstet Gynecol; 2013 Apr; 208(4):337-8. PubMed ID: 23295980 [No Abstract] [Full Text] [Related]
19. The rebirth of progesterone in the prevention of preterm labor. Schmouder VM; Prescott GM; Franco A; Fan-Havard P Ann Pharmacother; 2013 Apr; 47(4):527-36. PubMed ID: 23535817 [TBL] [Abstract][Full Text] [Related]
20. Progestational agents to prevent preterm birth: a meta-analysis of randomized controlled trials. Thangaratinam S; Coomarasamy A Obstet Gynecol; 2005 Jun; 105(6):1483-4; author reply 1484. PubMed ID: 15932848 [No Abstract] [Full Text] [Related] [Next] [New Search]